13F Holdings
中文EN

ZBH ZIMMER BIOMET HOLDINGS, INC.

Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1136869 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.0%
TTM net income YoY-4.7%
TTM EPS YoY-1.7%
Revenue 3-yr CAGR5.6%
Net income 3-yr CAGR17.4%

Margins

Gross margin69.7%
Operating margin13.6%
Net margin9.0%
FCF margin19.2%
EBITDA margin26.5%

Returns

ROE6.0%
ROA3.3%
ROIC (approx.)5.1%
Asset turnover0.36x

Leverage & solvency

Liabilities / assets45.9%
Debt / equity0.59x
Current ratio1.46x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.46x
Accruals ratio-4.8%
Payout ratio24.3%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$8.23B$7.68B$7.39B$6.94B$6.83B
Cost of revenue$2.49B$2.19B$2.08B$2.02B$1.96B
Gross profit$5.74B$5.49B$5.31B$4.92B$4.87B
R&D expense$458.50M$437.40M$458.70M$406.00M$435.80M
SG&A expense$3.26B$2.93B$2.84B$2.76B$2.84B
Operating income$1.10B$1.29B$1.28B$696.30M$860.30M
Pretax income$830.80M$1.04B$1.07B$403.50M$499.00M
Income tax$125.70M$131.40M$42.20M$112.30M$53.50M
Net income$705.10M$903.80M$1.02B$231.40M$401.60M
EBITDA$2.19B$2.28B$2.23B$1.62B$1.80B
EPS (basic)3.564.454.911.101.93
EPS (diluted)3.554.434.881.101.91
Dividends declared per share0.960.960.960.960.96
Weighted avg. shares (diluted)198.70M203.90M209.70M210.30M210.40M
Banking
Net interest income-$292.80M-$218.00M-$201.20M-$164.80M-$208.40M
Balance sheet
Cash & equivalents$591.90M$525.50M$415.80M$375.70M$378.10M
Receivables$1.70B$1.48B$1.44B$1.38B$1.26B
Inventory$2.29B$2.24B$2.39B$2.15B$2.15B
Current assets$5.12B$4.67B$4.61B$4.43B$4.88B
PP&E, net$2.21B$2.05B$2.06B$1.87B$1.84B
Goodwill$9.95B$8.95B$8.82B$8.58B$8.92B
Intangibles$4.72B$4.60B$4.86B$5.06B$5.53B
Total assets$23.09B$21.37B$21.50B$21.07B$23.46B
Current liabilities$2.58B$2.45B$2.86B$2.36B$3.47B
Short-term debt$587.10M$863.00M$900.00M$544.30M$1.61B
Long-term debt$6.93B$5.34B$4.87B$5.15B$1.00B
Total debt$7.52B$6.20B$5.77B$5.70B$2.61B
Total liabilities$10.39B$8.89B$9.01B$9.04B$10.79B
Shareholders' equity$12.70B$12.47B$12.48B$12.02B$12.66B
Net debt$6.93B$5.68B$5.35B$5.32B$2.23B
Cash flow statement
Operating cash flow$1.70B$1.50B$1.58B$1.36B$1.40B
Capital expenditure$224.50M$203.80M$291.10M$187.90M$143.60M
Free cash flow$1.47B$1.30B$1.29B$1.17B$1.26B
Investing cash flow-$1.98B-$888.10M-$778.90M-$522.00M-$443.30M
Financing cash flow$326.00M-$484.50M-$763.50M-$775.70M-$1.31B
Depreciation & amortization$1.09B$996.30M$951.70M$926.40M$937.70M
Stock-based compensation$90.20M$101.00M$99.80M$105.00M$76.00M
Dividends paid$190.30M$196.00M$200.90M$201.20M$200.10M
Share buybacks$487.00M$868.00M$692.20M$126.40M—

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.